Bano Saira, Jawed Inshal, Abdul Qadir Muhammad Umair, Abbas Rizvi Syed Ali Farhan, Karmani Vikash Kumar, Alam Farah, Haseeb Abdul, Khan Hina, Mirza Agha Muhammad Wali, Akhtar Naheed, Bin Gulzar Abu Huraira, Hussien Mohamed Ahmed Khabab Abbasher
Bahria University, Medical and Dental College, Karachi 44000, Pakistan.
Dow University of Health sciences, Karachi 74200, Pakistan.
Transfus Apher Sci. 2025 Feb;64(1):104036. doi: 10.1016/j.transci.2024.104036. Epub 2024 Nov 23.
Systemic sclerosis (SSc) is an autoimmune disorder with fibrosis in multiple organs, autoantibodies, and microvascular abnormalities. Its origin is unclear, but it may result from circulatory damage, collagen metabolism disruption, and modifications in immunoregulation. The disease affects various organs and has high morbidity and mortality rates. SSc-related complications are managed using immunosuppressive medications that target autoantibodies. The main objective of this study was to assess the safety and efficacy of plasma therapy/plasmapheresis in managing SSc.
This systematic review followed PRISMA and IMRAD guidelines, using PICO framework for study selection based on MeSH terms and Boolean operators. It included cross-sectional, randomized control trials, and clinical studies on plasma therapy for SSc. Standardized protocols were used for data extraction and risk of bias assessment.
Plasma therapy is a growing treatment option for managing SSc with reported benefits, especially in early stages and specific organ complications. However, further investigation and standardized protocols are needed. This review explores the potential of plasma therapy in improving the quality of life for SSc patients and in combination with other treatments.
The review analyzed 15 articles, including research papers, controlled trials, and case reports. Plasma therapy, involving Plasmapheresis and therapeutic plasma exchange (TPE), improved symptoms of SSc like Raynaud phenomenon, vasculitis, muscle dysfunction, and digital ulcers. However, outcomes varied among studies, and some advanced cases showed limited benefits.
Plasma therapy can be an effective way of managing the symptoms of systemic sclerosis with low incidence of adverse events. However, the exact mechanism behind this treatment is still unclear. Therefore, additional studies are required.
